Resapp Health : Bioshares Biotech Summit Presentation

Digital healthcare for respiratory disease

Tony Kea)ng

Chief Execu)ve Officer and Managing Director [e-mail]

12th Bioshares Biotech Summit 29-30 July 2016

ASX: RAP

Disclaimer

This presenta)on has been prepared by ResApp Health Limited ("ResApp"). The informa)on contained in this presenta)on is a professional opinion only and is given in good faith. Certain informa)on in this document has been derived from third par)es and though ResApp has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by ResApp. Any forward-looking statements included in this document involve subjec)ve judgment and analysis and are subject to uncertain)es, risks and con)ngencies, many of which are outside the control of, and may be unknown to, ResApp. In par)cular, they speak only as of the date of this document, they assume the success of ResApp's strategies, and they are subject to significant regulatory, business, compe))ve and economic uncertain)es and risks. Actual future events may vary materially from the forward-looking statements and the assump)ons on which the forward-looking statements are based. Recipients of this document (Recipients) are cau)oned to not place undue reliance on such forward-looking statements. ResApp makes no representa)on or warranty as to the accuracy, reliability or completeness of informa)on in this document and does not take responsibility for upda)ng any informa)on or correc)ng any error or omission which may become apparent a^er this document has been issued.

To the extent permi_ed by law, ResApp and its officers, employees, related bodies corporate and agents (Agents) disclaim all liability, direct, indirect or consequen)al (and whether or not arising out of the negligence, default or lack of care of ResApp and/or any of its Agents) for any loss or damage suffered by a Recipient or other persons arising out of, or in connec)on with, any use or reliance on this presenta)on or informa)on.

This presenta)on is not an offer, invita)on, solicita)on or recommenda)on with respect to the subscrip)on for, purchase or sale of any security, and neither this presenta)on nor anything in it shall form the basis for any contract or commitment whatsoever.

All amounts in Australian dollars unless stated otherwise.

2

Digital healthcare for respiratory disease

• Developing the world's first clinically-tested, regulatory-approved respiratory disease diagnos)c test and management tools for smartphones

  • No addi'onal hardware needed

• Huge global market, 700M+ doctor visits annually for respiratory disease1

  • Unique opportunity to integrate into telehealth providers' exis)ng plaforms

  • Strong demand also seen within clinics, emergency rooms and outpa)ent facili)es

• Compelling clinical evidence with 1,430 pa)ents enrolled in pediatric and adult studies

• Successful Pre-Submission mee)ng held with US FDA, targe)ng US approval in early 2017

• US clinical study to begin in Q3 2016, Massachuse_s General Hospital announced as first site

• Strong balance sheet with $12.5M raised in March 2016

1. ResApp es)mate based on OECD doctor visits per capita data and assuming 10% of visits are for

respiratory disease (based on US data) 3

Company overview

Capital Structure (ASX:RAP)
Market Cap.	$240M
Share Price as of 25 July 2016	$0.37
Shares on Issue1	650M
Performance Shares2	93.75M
Op)ons3	15.5M
Staff Incen)ve Op)ons4	25M
Cash Balance as of 29 April 2016	$14.9M

1. Includes 57.2M escrowed shares (un)l 14/7/17)

2. Issued on achieving $20M of annual revenue or on an acquisi)on

3. 10M, exercise price of 2.6c, expire 31/12/16; 4.5M, exercise price of 28c, expire 29/4/19; 1.87M, exercise price of 30c, expire 29/4/19

4. Issued to MD, 5M op)ons at exercise price of 2.5c, 5M at 5c and 10M at 10c, 5 year expiry; Issued to Dr Abeyratne, 3M at 5c and 2M at 10c

Board of Directors

Dr Roger Aston Non-Execu)ve Chairman

(Chairman of Oncosil, former CEO of Mayne Pharma, Cambridge An)body, cofounder of pSivida Corp)

Dr Tony Kea)ng Managing Director and CEO

(former Director, Commercial Engagement of UniQuest, engineering management roles with Exa Corpora)on)

Mr Brian Leedman Execu)ve Director and VP

(Chair of AusBiotech-WA, co-founder of Imugene Ltd and Oncosil Medical Ltd, former VP, IR at pSivida Corp. and Group Marke)ng Manager at E&Y-WA)

Mr Chris Ntoumenopoulos Non-Execu)ve Director

(14+ years investment banking, Associate Director at CPS Capital, formerly at Ci)group, Indian Ocean Capital)

Substan)al Shareholders

Freeman Road: 6.84% Fidelity Interna)onal: 5.06%

4